NASDAQ NMS - GLOBAL MARKET · ZVRA
-0.84% · -$0.1000 · Vol 1.5M
Market closed · last close 4:00 PM ET · price as of 17:40:30 ET
Zevra Therapeutics Inc

Zevra Therapeutics Inc

Pharmaceuticals
$11.74
Card
Relationship Map

Follow $ZVRA

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ZVRA by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Analyst data unavailable at compute time
ZVRA
Zevra Therapeutics Inc
Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

48/ 100
Veridion Score
Middle range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: MEDIUM · 5 of 6 factors measured · Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ZVRA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ZVRA catalysts
About Zevra Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2015
Employees
61
Country
US

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$11.76
Day high
$11.93
Day low
$11.52
Previous close
$11.84
52W high
$14.75
-20.41% from high
52W low
$7.67
57% of range
Market cap
$703.1M
P/E
12.24×
EPS
$1.94
Beta
0.53
Shares out
59.4M
Volume
1.5M
1.66× rel vol
Avg volume
891K
VWAP
$11.66
Price history computed in-house
1W
-2.25%
1M
-1.26%
3M
-8.99%
1Y
+53.06%
YTD
+31.03%
SMA 50 $11.66 · above
SMA 200 $10.43 · above
52W position 57%

ZVRA overview

Loading financial statements
Loading ZVRA Form 4 filings
Public disclosures

Congress activity in ZVRA

No receipt-qualified Congressional disclosure is present for ZVRA in the cached public ledger.

Federal contracts

ZVRA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ZVRA in this window.
Lobbying spend

ZVRA lobbying filings, year to date.

Registered lobbying filings matched to Zevra Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ZVRA in this window.
Loading news for ZVRA
Analyst ratings
Sovereign unlock shows live analyst consensus for ZVRA.
Options
Sovereign unlock shows live options positioning for ZVRA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.